Nordic Nanovector and Heidelberg Pharma GmbH have entered a research agreement to develop novel treatment for leukaemia.

According to the agreement, the two partners will jointly develop novel antibody drug conjugates (ADCs) to treat leukaemia.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The agreement enables Nordic Nanovector to strengthen its product pipeline.

Myriad RBM and Sanofi have entered an agreement to analyse the cardiovascular risk in diabetic patients using biomarkers analysis.

"Myriad RBM and Sanofi have entered an agreement to analyse the cardiovascular risk in diabetic patients using biomarkers analysis."

Under the agreement, Sanofi will be responsible to provide 5,300 serum samples of patients from evaluation of Lixisenatide in acute coronary syndrome (ELIXA) trial. Myraid RBM will analyse the samples with CustomMAP platform to identify the biomarkers to predict cardiovascular and microvascular risk in diabetic patients.

Relief Therapeutics and FirstString Research have entered a partnership to further advance the clinical development of atexakin alfa in the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

According to the agreement, FristString will gain financial support from the US Government to submit an investigational new drug (IND) application of the drug to the FDA.

The agreement allows the partners to strengthen their research and commercial relationship.

Ritter Pharmaceuticals plans for an underwritten public offering of its common stock shares. Aegis Capital is acting as a sole book running manager to the company for the offering.

The company plans to use the funds to increase the working capital and for other general corporate purposes.

Everstone Capital Management has invested $33m to acquire a 70% stake in Rubicon Research.

The company has acquired the stakes from Kotak Private Equity and another undisclosed private investor.

Rubicon Research will use the funds to accelerate its growth.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact